MVCD4
MCID: MCR133
MIFTS: 42

Microvascular Complications of Diabetes 4 (MVCD4)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 4

MalaCards integrated aliases for Microvascular Complications of Diabetes 4:

Name: Microvascular Complications of Diabetes 4 57 74 29 13 6 40
Diabetic Nephropathy 74 72
Mvcd4 57 74
Microvascular Complications of Diabetes, Susceptibility to, 4 57
Nephropathy, Diabetic, Susceptibility to 57
Nephropathy, Diabetic 57

Classifications:



External Ids:

MeSH 44 D048909
UMLS 72 C0011881

Summaries for Microvascular Complications of Diabetes 4

UniProtKB/Swiss-Prot : 74 Microvascular complications of diabetes 4: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 4, also known as diabetic nephropathy, is related to atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease and microvascular complications of diabetes 3. An important gene associated with Microvascular Complications of Diabetes 4 is IL1RN (Interleukin 1 Receptor Antagonist). The drugs Pioglitazone and Zaleplon have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas.

More information from OMIM: 612628 PS603933

Related Diseases for Microvascular Complications of Diabetes 4

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 4 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 421)
# Related Disease Score Top Affiliating Genes
1 atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease 12.3
2 microvascular complications of diabetes 3 12.1
3 microvascular complications of diabetes 7 12.0
4 microvascular complications of diabetes 6 11.9
5 microvascular complications of diabetes 5 11.6
6 diabetic angiopathy 11.6
7 microvascular complications of diabetes 1 11.4
8 microvascular complications of diabetes 2 11.4
9 feigenbaum bergeron richardson syndrome 11.3
10 end stage renal failure 10.6
11 fibrosis of extraocular muscles, congenital, 1 10.5
12 hypertension, essential 10.5
13 neuropathy 10.4
14 kidney hypertrophy 10.4
15 kidney disease 10.4
16 hypercholesterolemia, familial, 1 10.3
17 hyperglycemia 10.3
18 atherosclerosis susceptibility 10.3
19 nephrosclerosis 10.3
20 hyperuricemia 10.3
21 diabetic neuropathy 10.3
22 hypoglycemia 10.3
23 proteasome-associated autoinflammatory syndrome 1 10.3
24 yemenite deaf-blind hypopigmentation syndrome 10.3
25 muscle hypertrophy 10.3
26 glucose intolerance 10.3
27 cytokine deficiency 10.3
28 arteries, anomalies of 10.3
29 hyperlipoproteinemia, type iii 10.3
30 coronary artery anomaly 10.3
31 congestive heart failure 10.3
32 cerebrovascular disease 10.3
33 diabetes mellitus 10.3
34 wilms tumor 5 10.3
35 systemic lupus erythematosus 10.2
36 homocysteinemia 10.2
37 focal segmental glomerulosclerosis 10.2
38 creatinine clearance quantitative trait locus 10.2
39 deficiency anemia 10.2
40 lipoid nephrosis 10.2
41 rapidly involuting congenital hemangioma 10.2
42 arterial calcification, generalized, of infancy, 1 10.2
43 eclampsia 10.2
44 b-cell lymphoma 10.2
45 autoimmune disease 10.2
46 wilms tumor 1 10.2
47 body mass index quantitative trait locus 1 10.2
48 coronary heart disease 1 10.2
49 arteriolosclerosis 10.2
50 vasculitis 10.2

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 4:



Diseases related to Microvascular Complications of Diabetes 4

Symptoms & Phenotypes for Microvascular Complications of Diabetes 4

Clinical features from OMIM:

612628

Drugs & Therapeutics for Microvascular Complications of Diabetes 4

Drugs for Microvascular Complications of Diabetes 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 351)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
3
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
4
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
5
Atenolol Approved Phase 4 29122-68-7 2249
6
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
7
Methyldopa Approved Phase 4 555-30-6 38853
8
Clonidine Approved Phase 4 4205-90-7 2803
9
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
10
Capsaicin Approved Phase 4 404-86-4 1548943
11
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
12
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
13
Probucol Approved, Investigational Phase 4 23288-49-5 4912
14
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
15
Ramipril Approved Phase 4 87333-19-5 5362129
16
Doxazosin Approved Phase 4 74191-85-8 3157
17
Indapamide Approved Phase 4 26807-65-8 3702
18
Atorvastatin Approved Phase 4 134523-00-5 60823
19
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
20
Trandolapril Approved Phase 4 87679-37-6 5484727
21
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
22
Nisoldipine Approved Phase 4 63675-72-9 4499
23
Insulin glargine Approved Phase 4 160337-95-1
24
Insulin glulisine Approved Phase 4 207748-29-6
25
Liraglutide Approved Phase 4 204656-20-2 44147092
26
Allopurinol Approved Phase 4 315-30-0 2094
27
Nitric Oxide Approved Phase 4 10102-43-9 145068
28
Insulin Lispro Approved Phase 4 133107-64-9
29
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
30
Glimepiride Approved Phase 4 93479-97-1 3476
31
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
32
Febuxostat Approved Phase 4 144060-53-7 134018
33
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
34
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
35
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
36
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
37
Amlodipine Approved Phase 4 88150-42-9 2162
38
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
39
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
40
Terazosin Approved Phase 4 63590-64-7 5401
41
Hydralazine Approved Phase 4 86-54-4 3637
42
Gliclazide Approved Phase 4 21187-98-4 3475
43
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
44
Metformin Approved Phase 4 657-24-9 4091 14219
45
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
46
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
47
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
48
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
49
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354

Interventional clinical trials:

(show top 50) (show all 376)
# Name Status NCT ID Phase Drugs
1 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
2 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Unknown status NCT03147677 Phase 4 Alfacalcidol;Irbesartan
3 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
4 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
5 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
6 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
7 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
8 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
9 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
10 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
11 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Unknown status NCT02690883 Phase 4 Exenatide;Lispro
12 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
13 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
14 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
15 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
16 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
17 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
18 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
19 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
20 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
21 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
22 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
23 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
24 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
25 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
26 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
27 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
28 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
29 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
30 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
31 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
32 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
33 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
34 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide
35 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
36 A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria Completed NCT02829177 Phase 4 Allopurinol;Placebo
37 A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil
38 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
39 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
40 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
41 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
42 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
43 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
44 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
45 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4 Ramipril
46 The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension Completed NCT00921570 Phase 4 Amlodipine;Valsartan
47 Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose Completed NCT01738945 Phase 4 Amlodipine
48 A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA. Completed NCT01191983 Phase 4 Methoxy polyethylene glycol-epoetin beta [Mircera]
49 A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Derivative Glimepiride on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus (T2DM) Completed NCT02106104 Phase 4 Linagliptin 5 mg QD (N=24);Glimepiride 1 mg QD (N=24)
50 Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study" Completed NCT02585804 Phase 4 Dapagliflozin

Search NIH Clinical Center for Microvascular Complications of Diabetes 4

Inferred drug relations via UMLS 72 / NDF-RT 51 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 4

Genetic tests related to Microvascular Complications of Diabetes 4:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 4 29 IL1RN

Anatomical Context for Microvascular Complications of Diabetes 4

MalaCards organs/tissues related to Microvascular Complications of Diabetes 4:

41
Kidney, Endothelial, Pancreas, Bone, Heart, Liver, Monocytes

Publications for Microvascular Complications of Diabetes 4

Articles related to Microvascular Complications of Diabetes 4:

(show top 50) (show all 17286)
# Title Authors PMID Year
1
Polymorphisms in interleukin-1 beta and Interleukin-1 receptor antagonist genes are associated with kidney failure in Korean patients with type 2 diabetes mellitus. 38 8 71
15286433 2004
2
Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. 38 8 71
8786086 1996
3
Interleukin-1 system gene polymorphisms are associated with fat mass in young men. 71
16636119 2006
4
Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. 71
10750554 2000
5
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. 71
10746728 2000
6
Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. 71
10025794 1999
7
Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. 71
8500797 1993
8
Association of the polymorphisms in FOXO1 gene and diabetic nephropathy risk. 38
30987438 2019
9
Knockdown of ANGPTL-4 inhibits inflammatory response and extracellular matrix accumulation in glomerular mesangial cells cultured under high glucose condition. 38
31387395 2019
10
Arbutin protects HK-2 cells against high glucose-induced apoptosis and autophagy by up-regulating microRNA-27a. 38
31319730 2019
11
Silence of lncRNA GAS5 alleviates high glucose toxicity to human renal tubular epithelial HK-2 cells through regulation of miR-27a. 38
31159592 2019
12
Effects of autophagy on macrophage adhesion and migration in diabetic nephropathy. 38
31352855 2019
13
Diagnostic value of neutrophil gelatinase-associated lipocalin in diabetic nephropathy: a meta-analysis. 38
31215304 2019
14
circLRP6 regulates high glucose-induced proliferation, oxidative stress, ECM accumulation, and inflammation in mesangial cells. 38
31087368 2019
15
Demethoxycurcumin: A naturally occurring curcumin analogue for treating non-cancerous diseases. 38
31344992 2019
16
Pathological spectrum of glomerular disease in patients with renal insufficiency: a single-center study in Northeastern China. 38
31198075 2019
17
Critical role of mitochondrial dysfunction and impaired mitophagy in diabetic nephropathy. 38
31032918 2019
18
miR-15b-5p ameliorated high glucose-induced podocyte injury through repressing apoptosis, oxidative stress, and inflammatory responses by targeting Sema3A. 38
31025335 2019
19
Epidemiology investigation and analysis of patients with hemodialysis in Sichuan province of China. 38
31296088 2019
20
Apolipoprotein E genetic polymorphism influence the susceptibility to nephropathy in type 2 diabetes patients. 38
31357022 2019
21
Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin. 38
31310751 2019
22
Restorative potentiality of S-allylcysteine against diabetic nephropathy through attenuation of oxidative stress and inflammation in streptozotocin-nicotinamide-induced diabetic rats. 38
30062492 2019
23
1α,25(OH)2 D3 alleviates high glucose-induced lipid accumulation in rat renal tubular epithelial cells by inhibiting SREBPs. 38
31020705 2019
24
Sulfiredoxin-1 alleviates high glucose-induced podocyte injury though promoting Nrf2/ARE signaling via inactivation of GSK-3β. 38
31284950 2019
25
Overexpression of Circulating Soluble Nogo-B Improves Diabetic Kidney Disease by Protecting the Vasculature. 38
31217174 2019
26
LC3 promotes the nuclear translocation of the vitamin D receptor and decreases fibrogenic gene expression in proximal renal tubules. 38
31226352 2019
27
Clinical and histological features and therapeutic strategies for IgA nephropathy. 38
30968243 2019
28
Urinary biomarkers of tubular injury to predict renal progression and end stage renal disease in type 2 diabetes mellitus with advanced nephropathy: A prospective cohort study. 38
31227289 2019
29
Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications. 38
31301955 2019
30
Effects of PPARs/20-HETE on the renal impairment under diabetic conditions. 38
31163124 2019
31
PC-1 NF suppresses high glucose-stimulated inflammation and extracellular matrix accumulation in glomerular mesangial cells via the Wnt/β-catenin signaling. 38
31410160 2019
32
Methylglyoxal as a prognostic factor in patients with chronic kidney disease. 38
30407693 2019
33
Advanced Oxidation Protein Products Promote Lipotoxicity and Tubulointerstitial Fibrosis via CD36/β-Catenin Pathway in Diabetic Nephropathy. 38
31084358 2019
34
Biomarker panels associated with progression of renal disease in type 1 diabetes. 38
31222504 2019
35
Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity. 38
31124035 2019
36
Complement deposition on renal histopathology of patients with diabetic nephropathy. 38
30243617 2019
37
Influence of antioxidants' gene variants on risk of diabetes mellitus and its complications: a systematic review. 38
28548478 2019
38
A negative feedback loop of H19/miR-675/EGR1 is involved in diabetic nephropathy by downregulating the expression of the vitamin D receptor. 38
30815865 2019
39
Ski-related novel protein suppresses the development of diabetic nephropathy by modulating transforming growth factor-β signaling and microRNA-21 expression. 38
30847937 2019
40
Should we add atorvastatin to irbesartan for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials. 38
31152787 2019
41
Identification of clinical predictors of diabetic nephropathy and non-diabetic renal disease in Chinese patients with type 2 diabetes, with reference to disease course and outcome. 38
30927104 2019
42
Serum levels of immunoglobulin G and complement 3 differentiate non-diabetic renal disease from diabetic nephropathy in patients with type 2 diabetes mellitus. 38
31004313 2019
43
LncRNA NEAT1 promotes extracellular matrix accumulation and epithelial-to-mesenchymal transition by targeting miR-27b-3p and ZEB1 in diabetic nephropathy. 38
30549040 2019
44
Progranulin alleviates podocyte injury via regulating CAMKK/AMPK-mediated autophagy under diabetic conditions. 38
31402399 2019
45
Oleanolic acid attenuated diabetic mesangial cell injury by activation of autophagy via miRNA-142-5p/PTEN signaling. 38
31410746 2019
46
ER stress response mediates diabetic microvascular complications. 38
31430543 2019
47
Salivary and serum cystatin SA levels in patients with type 2 diabetes mellitus or diabetic nephropathy. 38
31174096 2019
48
Long noncoding RNA NONHSAG053901 promotes diabetic nephropathy via stimulating Egr-1/TGF-β-mediated renal inflammation. 38
30927260 2019
49
Dysregulation of microRNA-181b and TIMP3 is functionally involved in the pathogenesis of diabetic nephropathy. 38
30937907 2019
50
Prognostic nomogram and score to predict renal survival of patients with biopsy-proven diabetic nephropathy. 38
31401150 2019

Variations for Microvascular Complications of Diabetes 4

ClinVar genetic disease variations for Microvascular Complications of Diabetes 4:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 IL1RN IL1RN, IVS2, 86-BP DUP duplication Pathogenic,risk factor

Expression for Microvascular Complications of Diabetes 4

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 4.

Pathways for Microvascular Complications of Diabetes 4

GO Terms for Microvascular Complications of Diabetes 4

Sources for Microvascular Complications of Diabetes 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....